01 What is Kisspeptin?
In plain English.
Kisspeptin is a signalling molecule your own body makes in the brain. It is encoded by a gene called KISS1 and acts like the master switch that starts the whole reproductive hormone system. When kisspeptin neurons fire, they prompt the release of GnRH (gonadotropin-releasing hormone), which in turn drives the pituitary to release LH and FSH — the hormones that run puberty, the menstrual cycle, ovulation and testosterone production. It was originally discovered as a cancer-metastasis suppressor gene (hence the old name metastin) before its role in reproduction was understood. Much of the leading human research comes from Professor Waljit Dhillo's group at Imperial College London.
Two forms dominate the research: kisspeptin-54 (the longer, longer-lasting fragment) and kisspeptin-10 (a short, fast-acting fragment). Both bind the same receptor. Importantly, kisspeptin is a genuine, peer-reviewed area of endocrinology — not a fringe idea. But that scientific credibility is exactly why it is also marketed online as a "libido peptide". The trial data are real and interesting; the consumer product positioning runs far ahead of what has actually been shown.
02 How it works
The simple version, then the science.
Think of the reproductive system as a chain of command. Kisspeptin sits at the very top. It signals the brain to release GnRH, which is the trigger hormone for everything downstream — LH and FSH from the pituitary, then oestrogen, progesterone or testosterone from the ovaries or testes. Because it acts so far upstream, a single well-timed kisspeptin signal can set off a clean, natural hormone surge rather than over-riding the system the way a synthetic hormone does. In sexual-desire research, brain-imaging studies suggest it also influences the brain circuits that process sexual and emotional cues, not just the hormone cascade.
Go deeper · the proposed mechanism
Kisspeptin is the peptide product of the KISS1 gene and signals through KISS1R (also called GPR54), a G-protein-coupled receptor expressed on GnRH neurons in the hypothalamus. Binding drives the pulsatile secretion of GnRH, which sets the frequency and amplitude of pituitary LH and FSH release and thereby governs gonadal steroidogenesis and gametogenesis. Loss-of-function mutations in KISS1R cause idiopathic hypogonadotropic hypogonadism and failure to enter puberty, which is what first established kisspeptin as the gatekeeper of the hypothalamic-pituitary-gonadal axis. Beyond the neuroendocrine cascade, functional MRI work (Comninos, Dhillo et al.) shows kisspeptin administration modulates limbic and paralimbic activity in response to sexual and emotional stimuli, suggesting a central behavioural component distinct from its purely hormonal action.
03 What it's used for
Each use graded by how strong the evidence actually is.
- LimitedIVF / egg-maturation trigger🔬 In fertility trials at Imperial College London (Abbara, Jayasena, Dhillo et al.), a single dose of kisspeptin-54 has been used to trigger final egg maturation before egg collection, including in women at high risk of ovarian hyperstimulation syndrome (OHSS). Early-phase human studies suggest it can mature eggs with a potentially lower OHSS risk than standard hCG triggers. Promising and well-conducted, but not yet a licensed clinical product.
- LimitedLow sexual desire (HSDD) in women and men🔬 Randomised, placebo-controlled trials from the Dhillo group reported that kisspeptin administration increased brain activity in regions tied to sexual and emotional processing, and improved some measures of sexual response in men with low desire and in women with hypoactive sexual desire disorder. Effects are early-stage and described by the researchers themselves as modest; this is proof-of-concept science, not an approved treatment.
- LimitedHypothalamic amenorrhoea & delayed puberty🔬 Because kisspeptin sits upstream of GnRH, it has been studied as a probe and potential treatment for conditions where the reproductive axis is switched off — such as hypothalamic amenorrhoea. Research-stage; used to understand and test the axis rather than as routine therapy.
- AnecdotalOnline "libido / desire" peptide💬 Kisspeptin is sold by research-chemical vendors and some biohacking outlets as a libido or "desire" enhancer. This positioning borrows the credibility of the real trials but goes far beyond them: there is no approved product, no validated consumer dose, and unregulated vials cannot be verified for identity, purity or sterility.
04 What the evidence says
The science here is legitimate and unusually well-conducted for a peptide marketed online — but it is early. The strongest body of work comes from Professor Waljit Dhillo's group at Imperial College London. On fertility, Abbara, Jayasena and colleagues have run a series of trials using kisspeptin-54 to trigger egg maturation in IVF, with particular interest in reducing the risk of ovarian hyperstimulation syndrome compared with standard hCG triggers. On sexual function, randomised placebo-controlled studies (Comninos et al., and later work in both men and women) combined kisspeptin administration with functional MRI and reported changes in brain activity in regions that process sexual and emotional stimuli, alongside some improvement in sexual-response measures. Two honest caveats. First, sample sizes are small and the behavioural effects the authors report are modest and proof-of-concept, not a demonstrated clinical benefit. Second, none of this has translated into an approved product — there is no licensed kisspeptin medicine for fertility or for low desire anywhere in the world. The right description is 'real, peer-reviewed, early human science', not 'a proven libido or fertility treatment'.
05 Dosing & administration
Reported in the literature, information not advice.
For context only — this is not a usage guide and there is no validated outpatient protocol. In research, kisspeptin is given by intravenous infusion or subcutaneous injection under direct clinical supervision, with the dose and form (kisspeptin-54 versus the shorter kisspeptin-10) chosen for the specific study endpoint, such as triggering egg maturation at a defined point in an IVF cycle. These are tightly controlled experimental settings. There is no established dose for self-administration, and buying kisspeptin from a research-chemical vendor to dose yourself sits entirely outside the boundary of tested medicine.
06 Side effects & safety
In the published human trials, kisspeptin has generally been well tolerated over the short term, with no serious safety signal reported at the doses studied. Because trials are small and short, the safety picture beyond the experimental window is genuinely unknown — there are no long-term or repeated-dosing safety data in healthy consumers, no data in pregnancy, and no characterisation of effects from chronic self-administration. As a hormone-axis trigger it could, in principle, disturb the reproductive system if used outside controlled conditions. The larger practical risk for anyone buying online is supply: research-chemical kisspeptin is unregulated, and identity, purity, dose accuracy and sterility cannot be verified. Anyone considering it for fertility or sexual-health reasons should speak to a clinician rather than self-source.
07 Where to buy
Sold "research use only", so verification matters more than price.
08 Legal & regulatory status
- UKNot licensed by the MHRA for any indication. Used only within approved clinical research. No legitimate consumer supply; online "research chemical" sales are unregulated.
- USNot FDA-approved. Investigational / research use only. No compounding pathway, because there is no approved kisspeptin product.
- EUNot authorised by the EMA. Research use only.
- SportKisspeptin is not specifically named on the WADA Prohibited List, but as a pharmacological substance with no current regulatory approval for human therapeutic use it is captured by category S0 ("Non-Approved Substances") and is prohibited at all times in tested sport.
09 Clinical studies & research
Primary sources. Read the science yourself.